Novavax, Inc.
NASDAQ:NVAXBiotechnology
-$0.18 today
- Market cap
- $1.31B
- Beta
- 2.41
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.54
Volume 4.24M
Average 4.58M
NVAX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Novavax, Inc.NASDAQ: NVAX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$543K, compared with $533.91M a year earlier. Trailing-twelve-month EBITDA was -$42.13M.
Context
- EBITDA amounted to 43.8% of revenue in FY2025, up 28.0 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $37.37M (-92.4%) for the fiscal year ending Dec 2026, a slowdown from the +555.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$543K-101.9% QoQ
- Last fiscal yearDec 2025
- $492.33M+555.7% YoY
- LTMMar 2026
- -$42.13M-107.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -100.1% | -144.7% | -44.6 pp |
| 1 year | +555.7% | -92.4% | -648.1 pp |
| 3-year CAGR | — | -64.4% | — |
| 5-year CAGR | -9.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 492.33M USD
- Year-over-year change
- +555.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 492.33M | +555.7% |
| FY2024 | 2024-12-31 | (108.04M) | +77.8% |
| FY2023 | 2023-12-31 | (487.39M) | +19.4% |
| FY2022 | 2022-12-31 | (604.71M) | +64.0% |
| FY2021 | 2021-12-31 | (1.68B) | — |
EBITDA vs competitors
How NVAX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -107.6% is the 5th highest of 8, against a peer median of -3.7%.
- EBITDA amounts to 7.1% of revenue for NVAX, versus a peer median of 57.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $154.5M USD | +28.1% | +148.3% | 22.8% | |
| LTM Mar 2026 | -$42.13M USD | -107.6% | — | 7.1% | |
| LTM Mar 2026 | -$67.53M USD | -3.7% | — | 148.9% | |
| LTM Mar 2026 | -$81.94M USD | +12.2% | — | — | |
| LTM Mar 2026 | -€90.14M EUR | -119.6% | — | 57.7% | |
| LTM Jun 2026 | -€941.06M EUR | -2167.6% | — | 35.6% | |
| LTM Jun 2026 | -$1.05B USD | -116.2% | — | — | |
| LTM Sep 2026 | -$2.46B USD | +16.4% | — | 97.2% | |
| Peer median (excluding NVAX) | — | -3.7% | +148.3% | 57.7% | |
Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 197.58M | 1.6B | 556.38M | 682.16M | 1.12B |
| Cost of Revenue | 0 | 902.64M | 343.77M | 202.74M | 71.14M |
| Gross Profit | 197.58M | 696.31M | 212.61M | 479.42M | 1.05B |
| Gross Margin | 100.0% | 43.5% | 38.2% | 70.3% | 93.7% |
| Research & Development | 2.53B | 1.24B | 737.5M | 391.17M | 336.82M |
| Selling, General & Admin | 298.36M | 488.69M | 468.95M | 337.19M | 150.35M |
| Operating Expenses | 1.88B | 1.34B | 779.13M | 728.35M | 489.07M |
| Depreciation & Amortization | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M |
| EBITDA | (1.68B) | (604.71M) | (487.39M) | (108.04M) | 492.33M |
| EBITDA Margin | -850.7% | -37.8% | -87.6% | -15.8% | 43.8% |
| Operating Income | (1.69B) | (644.74M) | (566.51M) | (248.93M) | 563.27M |
| Operating Margin | -853.6% | -40.3% | -101.8% | -36.5% | 50.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 21.13M | 19.88M | 14.42M | 20.08M | 22.55M |
| Other Income / Expenses | (27.96M) | (8.91M) | 23.48M | 72.32M | (121.1M) |
| Income Before Tax | (1.71B) | (653.65M) | (543.03M) | (176.62M) | 442.17M |
| Pre-Tax Margin | -867.8% | -40.9% | -97.6% | -25.9% | 39.4% |
| Income Tax Expense | 29.22M | 4.29M | 2.03M | 10.88M | 1.87M |
| Net Income | (1.74B) | (657.94M) | (545.06M) | (187.5M) | 440.3M |
| Net Margin | -882.5% | -41.1% | -98.0% | -27.5% | 39.2% |
| EPS (Basic) | (23.44) | (8.42) | (5.41) | (1.23) | 2.72 |
| EPS (Diluted) | (23.44) | (8.42) | (5.41) | (1.23) | 2.54 |
| Weighted Avg Shares | 74.4M | 78.18M | 100.77M | 152.19M | 161.99M |
| Weighted Avg Shares (Diluted) | 74.4M | 78.18M | 100.77M | 152.19M | 173.1M |
Novavax, Inc.
NASDAQ:NVAX
Intrinsic Alpha fair value
Locked
Current Price
$7.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.